Technology
Health
Biotechnology

Concert Pharmaceuticals

$10.51
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.07 (-0.66%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell CNCE and other stocks, options, ETFs, and crypto commission-free!

About

Concert Pharmaceuticals, Inc. Common Stock, also called Concert Pharmaceuticals, is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Read More Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Employees
71
Headquarters
Lexington, Massachusetts
Founded
2006
Market Cap
251.35M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
199.91K
High Today
$10.70
Low Today
$10.35
Open Price
$10.54
Volume
35.52K
52 Week High
$20.79
52 Week Low
$9.21

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
2014 IPO
US

News

Seeking AlphaMay 7

Concert Pharmaceuticals (CNCE) Investor Presentation - Slideshow

The following slide deck was published by Concert Pharmaceuticals, Inc. in conjunction with this event. 1 20 Click to enlarge Notes:...

72
Yahoo FinanceMay 7

Why Concert Pharmaceuticals, Inc.'s (NASDAQ:CNCE) CEO Pay Matters To You

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Roger Tung has been the CEO of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) since 2006. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. After that, we will consider the growth in the business. And finally - as a second measure of performance - we will look at the returns shareholders have received over the las...

36
Seeking AlphaMay 5

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q1 2019 Results - Earnings Call Transcript

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Q1 2019 Earnings Conference Call May 2, 2019 8:30 AM ET Company Participants Justine Koenigsberg - SVP, Corporate Communications and IR Roger Tung - Co-Founder, CEO, President & Director James Cassella - Chief Development Officer Marc Becker - CFO Nancy Stuart - COO Conference Call Participants Adam Walsh - Stifel, Nicolaus & Company Esther Hong - Janney Montgomery Scott Difei Yang - Mizuho Securities Operator Good morning, and welcome to the Concert P...

78

Earnings

-$0.93
$1.19
$3.32
$5.44
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.